Should we be screening for anti-Jsa?

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

4
Reader(s)
4
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 27 , ISSUE 3 (September 2011) > List of articles

Should we be screening for anti-Jsa?

Nancy M. Nikolis / Fouad Boctor / William Andrew Heaton / James Martone

Keywords : Jsa, antibody, antigen, low prevalence antigens, antibody screening

Citation Information : Immunohematology. Volume 27, Issue 3, Pages 104-106, DOI: https://doi.org/10.21307/immunohematology-2019-183

License : (Transfer of Copyright)

Published Online: 11-March-2020

ARTICLE

ABSTRACT

We analyzed our historic patient database at North Shore University Hospital and determined both the overall frequency of anti-Jsa and the frequency at which it was detected in combination with other alloantibodies to red blood cell (RBC) antigens. Screening cells used currently are negative for Jsa. Our data suggest that anti-Jsa would not be detected in 30 to 40 percent of patients in which it is the sole antibody present. Since 1996 the antibody was only detected when other antibodies were found in the screening process. We are exposing 1.7 percent of our patients (90 patients/year) to Jsa. The clinical significance of anti-Jsa is apparent with previous literature, and our conclusion is that additional studies should be performed to determine whether Jsa should be included in current antibody screening cells.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share